CAS 882697-00-9

3-(2H-1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole

CAS : 882697-00-9

Formule : C₁₆H₁₁BrN₂O₂

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 343.1747

Ref: IN-DA01C02Q

3-(Benzo[D][1,3]Dioxol-5-Yl)-5-(3-Bromophenyl)-1H-Pyrazole

CAS : 882697-00-9

3-(Benzo[D][1,3]Dioxol-5-Yl)-5-(3-Bromophenyl)-1H-Pyrazole

Degré de pureté : 98%

Masse moléculaire : 343.17g/mol

Ref: 54-OR1023233

Anle138b

CAS : 882697-00-9

Anle138b

Degré de pureté : ≥98%

Masse moléculaire : 343.17g/mol

Ref: 54-BUP13852

Anle138b

CAS : 882697-00-9

Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease

Formule : C₁₆H₁₁BrN₂O₂

Degré de pureté : 98.88% - 99.82%

Couleur et forme : Solid

Masse moléculaire : 343.17

Ref: TM-T5447

Anle 138b

Produit contrôlé

CAS : 882697-00-9

Applications Anle 138b is an anti-aggregating compound previously shown to delay the onset of scrapie, a transmissible prion disease. A protein aggregation inhibitor.
References Qin, K., et al.: J. Gen. Virol., 100, 1027 (2019); Matthes, D., et al.: ACS Chem. Neurosci., 8, 2791 (2017); Wagner, J., et al.: Acta Neuropathol.,130, 619 (2015)

Formule : C₁₆H₁₁BrN₂O₂

Couleur et forme : Neat

Masse moléculaire : 343.175

Ref: TR-A648250

Anle138b

CAS : 882697-00-9

Anle138b is a cyclic lipopeptide that belongs to the group of photochemically active substances. It has been shown to be effective in a number of animal models, including a model system for Alzheimer's disease, and has been shown to be clinically relevant in humans. Anle138b is being investigated as a treatment for cognitive impairment due to its ability to cross the blood-brain barrier and bind selectively to neurons. The drug has been shown to inhibit synaptic dysfunction and energy metabolism in these cells. Clinical trials are ongoing for Alzheimer's disease and other dementias.

Formule : C₁₆H₁₁BrN₂O₂

Degré de pureté : Min. 95%

Masse moléculaire : 343.17 g/mol

Ref: 3D-HKB69700